Praxis Precision Medicines Inc (PRAX)

04:39 AM

Praxis Precision Medicines Inc. Stock Analysis and ForecastFree Risk Assessment Services - Autocar Professional

04:39 AM

03:32 AM

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World

03:32 AM

01:51 AM

What drives Praxis Precision Medicines Inc. stock priceConsistent triple-digit returns - jammulinksnews.com

01:51 AM

Jul 22, 2025

Major Depressive Disorder Clinical Trials, Companies, - openPR.com

Jul 22, 2025

Jul 22, 2025

Is Praxis Precision Medicines Inc. a good long term investmentDynamic investment opportunities - jammulinksnews.com

Jul 22, 2025

Jul 22, 2025

What makes Praxis Precision Medicines Inc. stock price move sharplyFree Stock Selection - Newser

Jul 22, 2025

Jul 22, 2025

Does Praxis Precision Medicines Inc. stock pay reliable dividendsShort Squeeze Radar - Newser

Jul 22, 2025

Jul 22, 2025

Why Praxis Precision Medicines Inc. stock attracts strong analyst attentionGroup Only Stock Signals - Newser

Jul 22, 2025

Jul 21, 2025

What analysts say about Praxis Precision Medicines Inc. stockConsistent high-yield stocks - Autocar Professional

Jul 21, 2025

Jul 21, 2025

Praxis Precision Medicines’ (PRAX) Buy Rating Reiterated at HC Wainwright - Defense World

Jul 21, 2025

Jul 20, 2025

(PRAX) Trading Report - news.stocktradersdaily.com

Jul 20, 2025

Jul 19, 2025

Here's Why We're Not Too Worried About Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Situation - 富途牛牛

Jul 19, 2025

Jul 18, 2025

Praxis Precision Medicines stock gets BTD for relutrigine, H.C. Wainwright maintains Buy - Investing.com Nigeria

Jul 18, 2025

Jul 18, 2025

Praxis Precision Medicines stock gets BTD for relutrigine, H.C. Wainwright maintains Buy By Investing.com - Investing.com South Africa

Jul 18, 2025

Jul 18, 2025

PRAX: HC Wainwright & Co. Reiterates Buy Rating with $105 Target - GuruFocus

Jul 18, 2025

Jul 17, 2025

Praxis Precision gets FDA breakthrough therapy status for Relutrigine - Seeking Alpha

Jul 17, 2025

Jul 17, 2025

FDA grants breakthrough therapy designation to Praxis’ relutrigine for pediatric epilepsy - Investing.com Canada

Jul 17, 2025

Jul 17, 2025

Q1 Earnings Forecast for PRAX Issued By HC Wainwright - Defense World

Jul 17, 2025

Jul 17, 2025

Praxis Precision Medicines and the Breakthrough Potential of Relutrigine in Rare Epilepsy Therapies: Strategic and Financial Implications of FDA Breakthrough Therapy Designation - AInvest

Jul 17, 2025

Jul 17, 2025

Praxis Says FDA Grants Breakthrough Therapy Designation To Relutrigine For Rare Pediatric Epilepsies - Nasdaq

Jul 17, 2025

Jul 17, 2025

FDA grants breakthrough therapy status to Praxis’s relutrigine By Investing.com - Investing.com Canada

Jul 17, 2025

Jul 17, 2025

FDA grants breakthrough therapy status to Praxis’s relutrigine - Investing.com Australia

Jul 17, 2025

Jul 17, 2025

Praxis Precision Medicines Gains FDA Breakthrough Designation - TipRanks

Jul 17, 2025

Jul 17, 2025

PRAX Gains FDA Breakthrough Designation for Pediatric Epilepsy D - GuruFocus

Jul 17, 2025

Jul 17, 2025

Praxis Precision Medicines Receives Breakthrough Therapy Designation for Relutrigine in Pediatric Developmental and Epileptic Encephalopathies - Quiver Quantitative

Jul 17, 2025

Jul 17, 2025

Praxis Precision Medicines Receives FDA Breakthrough - GlobeNewswire

Jul 17, 2025

Jul 17, 2025

Praxis's Rare Epilepsy Drug Achieves FDA Breakthrough Status: 90% Seizure Reduction in Trial Patients - Stock Titan

Jul 17, 2025

Jul 15, 2025

How Praxis Precision Medicines Inc. stock performs during market volatilityLow Drawdown Trade Signals - Newser

Jul 15, 2025